NASDAQ (usa) |
![]() |
6715.56 | -12.11 | -0.18% |
FTSE 100 (london) |
![]() |
7487.96 | -5.12 | -0.07% |
DAX (german) |
![]() |
13465.51 | 235.94 | 1.78% |
NIKKEI 225 (japan) |
![]() |
22420.08 | 408.47 | 1.86% |
Hang - Seng (hong kong) |
![]() |
28594.06 | 348.52 | 1.23% |
NIFTY - 50 (india) | ||||
Straits Times (singapore) |
![]() |
3391.61 | 17.53 | 0.52% |
KOSPI (korea) |
![]() |
2556.47 | 33.04 | 1.31% |
All Ordinaries (australia) |
![]() |
6005.30 | 28.90 | 0.48% |
BOVESPA (brazil) |
![]() |
74092.76 | -215.73 | -0.29% |
Rain Therapeutics Inc (NASDAQ: RAIN)
RAIN Technical Analysis
5
As on 20th Feb 2025 RAIN SHARE Price closed @ 3.07 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 6.55 & Strong Sell for SHORT-TERM with Stoploss of 5.89 we also expect STOCK to react on Following IMPORTANT LEVELS. |
RAINSHARE Price
Open | 2.77 | Change | Price | % |
High | 3.23 | 1 Day | 1.86 | 153.72 |
Low | 2.62 | 1 Week | 1.87 | 155.83 |
Close | 3.07 | 1 Month | 1.89 | 160.17 |
Volume | 950 | 1 Year | -4.71 | -60.54 |
52 Week High 12.47 | 52 Week Low 0.82 |
NASDAQ USA Most Active Stocks
AMRS | 0.14 | 100.00% |
ADTX | 0.12 | -7.69% |
SMCI | 59.27 | -1.63% |
APTO | 0.19 | 26.67% |
INTC | 26.09 | 1.44% |
NVDA | 140.11 | 0.63% |
FGEN | 0.77 | 37.50% |
LMDX | 0.02 | 0.00% |
BHAT | 0.06 | 0.00% |
AKTS | 0.04 | 0.00% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
RAIN Daily Charts |
RAIN Intraday Charts |
Whats New @ Bazaartrend |
RAIN Free Analysis |
|
RAIN Important Levels Intraday
RESISTANCE | 4.25 |
RESISTANCE | 3.87 |
RESISTANCE | 3.64 |
RESISTANCE | 3.40 |
SUPPORT | 2.74 |
SUPPORT | 2.50 |
SUPPORT | 2.27 |
SUPPORT | 1.89 |
RAIN Forecast February 2025
4th UP Forecast | 9.18 |
3rd UP Forecast | 7.22 |
2nd UP Forecast | 6.01 |
1st UP Forecast | 4.8 |
1st DOWN Forecast | 1.34 |
2nd DOWN Forecast | 0.13 |
3rd DOWN Forecast | -1.08 |
4th DOWN Forecast | -3.04 |
RAIN Weekly Forecast
4th UP Forecast | 7.69 |
3rd UP Forecast | 6.21 |
2nd UP Forecast | 5.29 |
1st UP Forecast | 4.38 |
1st DOWN Forecast | 1.76 |
2nd DOWN Forecast | 0.85 |
3rd DOWN Forecast | -0.07 |
4th DOWN Forecast | -1.55 |
RAIN Forecast2025
4th UP Forecast | 29.39 |
3rd UP Forecast | 20.95 |
2nd UP Forecast | 15.73 |
1st UP Forecast | 10.51 |
1st DOWN Forecast | -4.37 |
2nd DOWN Forecast | -9.59 |
3rd DOWN Forecast | -14.81 |
4th DOWN Forecast | -23.25 |
Rain Therapeutics Inc ( NASDAQ USA Symbol : RAIN )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
RAIN Other Details
Segment | EQ | |
Market Capital | 416530272.00 | |
Sector | Healthcare | |
Industry | Biotechnology | |
Offical website | > echo $website ; ?> |
RAIN Address
![]() |
RAIN Latest News
RAIN Business Profile
Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is RAIN-32, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing RAIN-32 that has completed Phase II clinical trial in liposarcoma, Phase I clinical trial in solid tumors, and Phase II clinical trial in intimal sarcoma, as well as RAD52 for tumors, including breast, ovarian, prostate, and other cancers. Rain Therapeutics Inc. was incorporated in 2017 and is headquartered in Newark, California. Address: 8000 Jarvis Avenue, Newark, CA, United States, 94560-7467
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service